SPORE University of Texas M. D. Anderson Cancer Center-Leukemia

SPORE 德克萨斯大学 MD 安德森癌症中心 - 白血病

• 批准号: 10911713
• 负责人: Elizabeth J Shpall
• 金额: $ 91.86万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10911713
• 关键词: ATAC-seq; Achievement; Activated Natural Killer Cell; Acute Myelocytic Leukemia; Acute leukemia; Address; Administrator; Adoptive Transfer; Advocate; Aftercare; Allogenic; Antigens; Award; Azacitidine; B lymphoid malignancy; BCL1 Oncogene; BCL2 gene; Biological Markers; Blood; Blood Proteins; Bone Marrow; CAR T cell therapy; CASP9 gene; CD28 gene; CD70 antigen; Cancer Center; Cancer Center Support Grant; Caring; Cell Death; Cell Differentiation process; Cell Line; Cell Proliferation; Cell Shape; Cell Survival; Cell Therapy; Cell physiology; Cells; Cellular Stress; ChIP-seq; Chemoresistance; Chromatin; Clinic; Clinical; Clinical Protocols; Clinical Trials; Collaborations; Communication; Complement; Complex; Consultations; Cryopreservation; Cytarabine; Cytoplasm; DNA; Data; Databases; Dependence; Development; Disease; Disease remission; Doctor of Medicine; Dose; Doxorubicin; Drug Targeting; EZH2 gene; Electronic Mail; Eligibility Determination; Endogenous Retroviruses; Endowment; Engineering; Enrollment; Ensure; Event; Exhibits; Exposure to; FLT3 inhibitor; Future; Gene Silencing; Generations; Genes; Genetic Transcription; Genotype; Goals; Good Manufacturing Process; Grant; Hematologic Neoplasms; Hematopoietic stem cells; Hodgkin Disease; Human; IL3RA gene; In Vitro; In complete remission; Induction of Apoptosis; Infrastructure; Institution; Institutional Review Boards; Interferons; Interleukin-15; Laboratories; Leukemic Cell; Ligands; Liposomes; Lymphoid Cell; Maintenance; Marrow; Measures; Metabolic; Metabolism; Methods; Minority; Mitochondrial Electron Transport Complex I; Modality; Modeling; Monitor; Morphology; Multiple Myeloma; Mus; Mutation; National Cancer Institute; Natural Killer Cells; Nature; Neoadjuvant Therapy; Oncogenes; Organ; Outcome; Oxidative Phosphorylation; Pathogenesis; Pathologic; Pathology; Patients; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Phase I/II Clinical Trial; Phenotype; Phosphorylation Inhibition; Play; Policies; Population; Postremission Therapy; Preclinical Testing; Predisposition; Preparation; Prognosis; Progress Reports; Proliferating; Protein Array; Proteomics; Protocols documentation; Publications; Publishing; RNA; Refractory; Regulation; Relapse; Relaxation; Reporting; Reproduction spores; Research; Research Personnel; Research Project Grants; Residual Neoplasm; Residual state; Resistance; Retrotransposon; Risk; Safety; Sampling; Serum; Signal Transduction; Site; Specimen; Stem cell transplant; Strategic Planning; Stress; T-Lymphocyte; TNF gene; Testing; Texas; Therapeutic; Tissues; Toxic effect; Transcription Elongation; Transcription Initiation; Translational Research; Treatment Efficacy; Tumor Antigens; Tumor Burden; Umbilical Cord Blood; United States National Institutes of Health; Universities; University of Texas M D Anderson Cancer Center; Up-Regulation; Woman; Work; acute myeloid leukemia cell; adverse outcome; antileukemic activity; biobank; biological adaptation to stress; career; cell killing; cellular transduction; chemotherapeutic agent; chemotherapy; chimeric antigen receptor; cohort; cost; cytopenia; design; drug development; drug testing; ds-DNA; efficacy testing; engineered NK cell; experience; experimental study; first-in-human; genetically modified cells; graft vs host disease; improved; improved outcome; in vitro activity; in vitro testing; in vivo; inhibitor; inhibitor therapy; lectures; leukemia; leukemia relapse; leukemia treatment; leukemic stem cell; lymphoid neoplasm; manufacture; manufacturing process; meetings; member; mesenchymal stromal cell; metabolic fitness; mitochondrial fitness; mouse model; nanomolar; neoplastic cell; next generation; novel; novel therapeutics; older patient; overexpression; partial response; patient derived xenograft model; peripheral blood; pharmacodynamic biomarker; pharmacologic; point of care; prevent; progenitor; programs; prospective; protein expression; receptor; recruit; relapse patients; repository; response; screening; sensor; single cell analysis; small molecule; standard care; stem cells; success; suicide gene; symposium; synergism; targeted therapy trials; tool; transcriptome sequencing; transcriptomics; transplantation therapy; tumor; tumor heterogeneity; vector; weapons; web site

Project Abstract N/A

项目摘要 N/A。

项目成果

Ribosomal Proteins Rpl22 and Rpl22l1 Control Morphogenesis by Regulating Pre-mRNA Splicing.

• DOI: 10.1016/j.celrep.2016.12.034
• 发表时间: 2017-01-10
• 期刊: Cell reports
• 影响因子: 8.8
• 作者: Zhang Y;O'Leary MN;Peri S;Wang M;Zha J;Melov S;Kappes DJ;Feng Q;Rhodes J;Amieux PS;Morris DR;Kennedy BK;Wiest DL
• 通讯作者: Wiest DL

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.

• DOI: 10.1038/s41408-021-00453-z
• 发表时间: 2021-03-17
• 期刊: Blood cancer journal
• 影响因子: 12.8
• 作者: Reville PK;Kantarjian HM;Ravandi F;Jabbour E;DiNardo CD;Daver N;Pemmaraju N;Ohanian M;Alvarado Y;Xiao L;Alatrash G;Loghavi S;Rausch CR;Borthakur G;Konopleva M;Cortes J;Kadia TM
• 通讯作者: Kadia TM

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.

• DOI: 10.1038/leu.2016.393
• 发表时间: 2017-09
• 期刊: Leukemia
• 影响因子: 11.4
• 作者: Saenz DT;Fiskus W;Qian Y;Manshouri T;Rajapakshe K;Raina K;Coleman KG;Crew AP;Shen A;Mill CP;Sun B;Qiu P;Kadia TM;Pemmaraju N;DiNardo C;Kim MS;Nowak AJ;Coarfa C;Crews CM;Verstovsek S;Bhalla KN
• 通讯作者: Bhalla KN

CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.

• DOI: 10.3390/cancers14092287
• 发表时间: 2022-05-03
• 期刊: CANCERS
• 影响因子: 5.2
• 作者: Bole-Richard, Elodie;Pemmaraju, Naveen;Cael, Blandine;Daguindau, Etienne;Lane, Andrew A.
• 通讯作者: Lane, Andrew A.

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.

• DOI: 10.1038/s41408-023-00871-1
• 发表时间: 2023-06-29
• 期刊: BLOOD CANCER JOURNAL
• 影响因子: 12.8
• 作者: Senapati, Jayastu;Muftuoglu, Muharrem;Ishizawa, Jo;Abbas, Hussein A.;Loghavi, Sanam;Borthakur, Gautam;Yilmaz, Musa;Issa, Ghayas C.;Dara, Samuel I.;Basyal, Mahesh;Li, Li;Naqvi, Kiran;Pourebrahim, Rasoul;Jabbour, Elias J.;Kornblau, Steven M.;Short, Nicholas J.;Pemmaraju, Naveen;Garcia-Manero, Guillermo;Ravandi, Farhad;Khoury, Joseph;Daver, Naval;Kantarjian, Hagop M.;Andreeff, Michael;DiNardo, Courtney D.
• 通讯作者: DiNardo, Courtney D.